Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.544
Peer-review started: October 23, 2016
First decision: December 20, 2016
Revised: January 19, 2017
Accepted: February 8, 2017
Article in press: February 13, 2017
Published online: April 18, 2017
Processing time: 177 Days and 3.5 Hours
To survey the efficacy and safety of dual therapy with daclatasvir and asunaprevir in the elderly hepatitis C virus (HCV) patients multicentricity.
Interferon-ineligible/intolerant patients and non-responders to previous pegylated-interferon/ribavirin therapy with chronic HCV genotype 1b infection were enrolled. Child B, C cirrhotic patients were excluded. Patients received oral direct acting antiviral treatment consisting of 60 mg daclatasvir once daily plus 200 mg asunaprevir twice daily for 24 wk. We divided the patients into two groups of 56 elderly patients (≥ 75 years-old) and 141 non-elderly patients (< 75 years old) and compared the efficacy and safety.
Ninety-one point one percent of elderly patients and 90.1% of non-elderly patients achieved sustained virological response at 24 wk (SVR24). In the former, 1.8% experienced viral breakthrough, as compared with 3.5% in the latter (not significant). Adverse events occurred in 55.4% of the former and 56.0% of the latter. In the former, 7 cases (12.5%) were discontinued due to adverse events, and in the latter 9 cases were discontinued (6.4%, not significant).
Dual therapy with daclatasvir and asunaprevir achieved the same high rates of SVR24 in HCV elderly patients without more adverse events than in the non-elderly patients.
Core tip: Recently, it was demonstrated that dual oral therapy with daclatasvir and asunaprevir without pegylated-interferon/ribavirin was well tolerated and achieved high sustained virological response rates in Japanese patients with chronic hepatitis C virus genotype Ιb infection, including patients with liver cirrhosis (Child A stage). However, the efficacy and side effects of these drugs was previously studied in non-elderly patients (less than 70 years of age). Those in elderly patients, who are supposed to have higher incidence of hepatocellular carcinoma, have not been studied. We demonstrated that efficacy and side effects in elderly patients were nearly the same as in non-elderly patients.
- Citation: Tarao K, Tanaka K, Nozaki A, Sato A, Ishii T, Komatsu H, Ikeda T, Komatsu T, Matsushima S, Oshige K. Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World J Hepatol 2017; 9(11): 544-550
- URL: https://www.wjgnet.com/1948-5182/full/v9/i11/544.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i11.544
Recently, it was demonstrated that dual oral therapy with daclatasvir and asunaprevir without pegylated-interferon/ribavirin (PegIFNα/RBV) was well tolerated and achieved high sustained virological response (SVR) rates in difficult-to-treat Japanese patients with chronic hepatitis C virus (HCV) genotype Ib infection, including patients with liver cirrhosis (Child A stage)[1-4].
It is generally accepted that the average age of the patients with HCV-associated liver disease in Japan is increasing, and indeed patients more than 60 years of age represent more than 70% of all patients[5]. Moreover, Kumada et al[6] recently analyzed the age distribution of 3388 persistent HCV-infected patients and found that the median age was 70 years, and 2249 (66.4%) were elderly patients of more than 65 years.
Also, recently, Asahina et al[7] demonstrated that the risk for hepatocellular carcinoma (HCC) after interferon treatment was age-dependent and increased predominantly when the age at primary liver biopsy was > 65 years. They also demonstrated that progression of fibrosis over time was significantly accelerated in older patients. In addition, elderly patients with HCV-associated chronic hepatitis are thought to develop liver cirrhosis more rapidly, and HCC might develop more frequently as a result. An increase in the aged population is an impending problem, and we must eradicate the HCV infection as soon as possible in elderly patients.
We therefore retrospectively examined the efficacy and safety of dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protein inhibitor, asunaprevir, in elderly patients (≥ 75 years of age) with hepatitis C chronic hepatitis or liver cirrhosis (Child A stage), who may have suffered from longer periods of HCV infection, in many large hospitals in Kanagawa Prefecture in Japan.
This study included two populations of patients with HCV genotype 1b infection: Null responders (< 2 log10 decline in serum HCV RNA levels after 12 wk of prior PegIFNα/RBV), and PegIFNα/RBV ineligible/intolerant patients. The latter group was either patients who discontinued prior therapy with PegIFNα/RBV due to intolerance after < 12 wk, or patients who were treatment-naïve but poor candidates for PegIFN-α/RBV for medical reasons such as advanced age or complications of depression, anemia, myelosuppression, diabetes or cardiovascular or renal dysfunction. Of the cirrhotic patients, only those with Child-Pugh stage A were enrolled[8], and patients with Child-Pugh stages B and C were omitted.
The patients were out-patients and visited the following hospitals in Kanagawa Prefecture of Japan between 1 September 2014 and 30 March 2015: Tarao’s Gastroenterological Clinic, Yokohama City University Medical Center, Yokohama Seibu Hospital of St. Marianna University, Yokohama Municipal Citizens Hospital, Yokosuka General Hospital Uwamachi, and National Hospital Organization Yokohama Medical Center.
Elderly patients were defined as those equal to or over 75 years old. Enrolled patients were divided into two groups, elderly patients (≥ 75 years old) and non-elderly patients (< 75 years old), and efficacy and safety assessments were compared. The primary efficacy end-point was the proportion of patients with undetectable HCV RNA at 24 wk post-treatment (SVR24).
Written informed consent was obtained from all patients. The study was approved by institutional review boards in each hospital and conducted in compliance with the Declaration of Helsinki.
Eligible patients were men and women, aged 34-83 years, with HCV genotype 1 infection with chronic hepatitis or compensated liver cirrhosis. Patients with cirrhosis were confined to Child-Pugh stage A[8], and patients with stage B and C cirrhosis were excluded. Exclusionary laboratory findings included alanine aminotransferase (ALT) > 5 × upper limit of normal (ULN), total bilirubin > 2 mg/dL, albumin < 3.5 g/dL, hemoglobin < 9.0 g/dL, white blood cells < 1500 mm3, platelets < 50000/mm3, and creatinine > 1.8 × ULN. No patients had prior exposure to HCV direct-acting antivirals.
At prc-treatment points and the resistant-associated variants (RAVs) in NS5A (Y93H) were investigated by PCR-invader assay. PCR-invader assays were conducted by BML Inc. (Saitama, Japan), and weakly positive and negative samples were defined as substitution-negative. In 132 out of 197 cases, the RAVs was examined and the results were as follows: Y93H ≤ 1% in 116 cases (87.9%), 2%-5% in 14 cases (10.6%), 23% in 1 case (7.6%), 64% in 1 case (7.6%).
Patients received 24 wk of treatment with 60 mg daclatasvir once daily combined with 200 mg asunaprevir twice daily, and participated in 24 wk of post-treatment follow-up. HCV RNA, physical examinations, adverse events, laboratory parameters and concomitant medications were assessed at day 1 (baseline), treatment weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24, and post-treatment weeks 4, 8, 12 and 24.
Pearson’s χ2 test and the Student’s t-test were used for statistical analyses. Statistical significance was considered to exist at P < 0.05.
A total of 197 patients were enrolled in this retrospective study, and included 56 elderly patients and 141 non-elderly patients. Backgrounds of the patients are shown in Table 1. In the elderly patients, the number of cirrhotic patients (53.6%) was significantly larger, as compared with 31.2% in the non-elderly patients (P = 0.003). The average age was 77.8 years in the elderly patients and 65.3 years in the non-elderly patients. The male/female ratio was nearly the same in the two groups (P = 0.719). HCV genotype was 1b in all patients. HCV RNA (mean log10 IU/mL) was 5.85 ± 0.77 in the former and 6.12 ± 0.70 in the latter (P = 0.016). Percentages of the non-responder patients in the prior PegIFNα/RBV therapy group were 17.9% in the former and 25.5% in the latter (P = 0.251).
| Parameter | Elderly patients, n = 56 | Non-elderly patients, n = 141 | P |
| Cirrhosis/chronic hepatitis | 30/26 | 44/97 | 0.003 |
| Age in years | 77.8 (75-83) | 65.3 (34-74) | |
| Male/female | 23/33 (41.1%/58.9%) | 54/87 (38.3%/61.7%) | |
| HCV genotype 1b, % | 100 | 100 | |
| HCV RNA, mean log10 IU/mL | 5.85 ± 0.77 | 6.12 ± 0.70 | |
| Pegylated-interferon/ribavirin non-responder, % | 17.9 | 25.5 | 0.251 |
Of the elderly patients, 51 (91.1%) achieved SVR24, while in the non-elderly patients, 127 (90.1%) achieved SVR24. The ratio of patients achieving SVR24 was nearly the same in the two groups (Table 2). The ratio of patients who achieved SVR24 in the group that discontinued due to side effects was 71.4% (5/7) for the elderly and 77.8% (7/9) for the non-elderly patients (Table 2).
| Parameter | Elderly patients, n = 56 | Non-elderly patients, n = 141 | P |
| SVR24 | 51 (91.1) | 127 (90.1) | |
| Viral breakthrough | 1 (1.8) | 5 (3.5) | 0.519 |
| Post-treatment relapse | 2 (3.6) | 7 (5.0) | 0.675 |
| Ratio of patients who achieved SVR24 in the discontinued cases due to side effects | 5/7 (71.4) | 7/9 (77.8) |
Only one patient out of 56 (1.8%) experienced viral breakthrough in the elderly group, as compared with 5 out of 141 (3.5%) in the non-elderly group (not significant, P = 0.519). Post-treatment relapse was seen in 2 (3.6%) of the elderly patients, as compared with 7 (5.0%) of the non-elderly patients (not significant, P = 0.675) (Table 2).
Adverse events and laboratory abnormalities in each group are shown in Table 3. There were no significant differences in each event between elderly and non-elderly groups. The total number of patients who showed adverse events in the elderly group was 31 out of 56 (55.4%), which was nearly the same in the non-elderly group (79 out of 141, 56.0%) (Table 4).
| Event | Elderly patients, n = 56 | Non-elderly patients, n = 141 |
| Nasopharyngitis | 5 (8.9) | 6 (4.3) |
| Headache | 4 (7.1) | 9 (6.4) |
| Diarrhea | 3 (5.4) | 5 (3.5) |
| Pyrexia | 2 (3.6) | 12 (8.5) |
| Malaise | 7 (12.5) | 8 (5.7) |
| Anorexia | 6 (10.7) | 8 (5.7) |
| AST elevation | 15 (26.8) | 55 (39.0) |
| ALT elevation | 14 (25.0) | 54 (38.3) |
| Hb decrease | 8 (14.3) | 11 (7.8) |
| Total bilirubin increase | 2 (3.6) | 11 (7.8) |
| Creatinine increase | 8 (14.3) | 13 (9.2) |
| Elderly patients | Non-elderly patients | |
| No. of total patients enrolled | 56 | 141 |
| No. of patients who experienced adverse events | 31 | 79 |
| Percentage of patients who experienced adverse events | 55.4 | 56.0 |
Table 5 shows the causes of discontinuation and the numbers of patients in whom the drugs were discontinued due to adverse effects in each group. The levels of elevation of ALT and total bilirubin at which the drug was discontinued were 200 INU (5-folds of normal) for ALT and 3.0 mg/dL for total bilirubin. In the elderly group, 7 out of 56 cases (12.5%) were discontinued, and in the non-elderly group, 9 out of 141 (6.4%). The ratio of discontinuation was greater for the elderly patients but the difference was not significant (P = 0.336). The ratio of patients who achieved SVR24 in the discontinued due to side effects subgroup was 71.4% (5/7) in the elderly and 77.8% (7/9) in the non-elderly patients (Table 2).
| Elderly patients | Non-elderly patients |
| 16 w Malaise, Anorexia1 | 18 w Elevation of ALT1 |
| 6 w Malaise, Anorexia1 | 6 w Elevation of ALT1 |
| 6 w Elevation of ALT1 | 2 w Pyrexia1 |
| 8 w Elevation of ALT1 | 3 w Pyrexia |
| 3 w Pyrexia | 13 w Sepsis due to hemolytic |
| 4 w Cough | streptococcus1 |
| 18 w Development of HCC1 | 18 w Abdominal fullness1 |
| 2 w Elongation of PT | |
| 3 w Elevation of total bilirubin1 | |
| 18 w Development of HCC1 | |
| Total 7/56 (12.5%) | 9/141 (6.4%) |
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
Informed consent was obtained from all patients for being included in the study. The protocol was approved by the ethics committees/institutional review boards of participating centers and conformed to Good Clinical Practice guidelines and Declaration of Helsinki principles. This article does not contain any studies with animal subjects.
In recent years, patients presenting with HCV-associated chronic hepatitis or liver cirrhosis have been older, especially those patients with liver cirrhosis[5-7]. Among these patients, the occurrence of HCC is also increasing. It is generally well accepted that aging is a potent risk factor for HCC development in patients with HCV-associated liver disease[7-11]. Peg-IFNα/RBV therapy was shown to be effective in preventing the development of HCC in younger patients[12]; however, older patients are poor candidates for Peg-IFNα/RBV therapy.
More recently, oral dual therapy with daclatasvir/asunaprevir was demonstrated to be very effective in eradicating HCV infection. Overall, 76.7% of patients achieved SVR12 and SVR24 in an initial trial[2].
In this study, we demonstrated that the proportion of patients with SVR at 24 wk post-treatment was almost the same among elderly patients (≥ 75 years old), who were thought to have longer durations of HCV infection, as among younger patients (< 75 years old, 91.1% vs 90.1%).
We also demonstrated that the degree of side effects was nearly the same in the elderly and younger patients. Hitherto, no report has dealt with age differences in the efficacy and side effects of oral dual administration of daclatasvir/asunaprevir. The question remains: Is there any essential benefit in eradicating HCV in elderly patients (≥ 75 years old) with HCV-associated liver disease by administering daclatasvir/asunaprevir?
There is much evidence that the eradication of HCV virus (i.e., SVR) by IFN or Peg-IFNα/RBV treatment brings about a low incidence of HCC development[12-18]. Yet, there is no definite evidence that the eradication of HCV virus by dual therapy with daclatasvir/asunaprevir can bring about a low incidence of HCC in SVR patients. There is some potential, however, for these drugs to lower the risk of HCC development. First, there is some evidence of lowering serum alfa-fetoprotein (AFP) levels after eradicating HCV virus by the dual therapy, which is one of the potential risk factors for HCC development in HCV-associated liver diseases[19-24]. Oka et al[25,26] actually demonstrated that the serum AFP level was a potential risk factor for HCC development in cirrhotic patients.
Karino et al[20] compared the changes of serum AFP levels after treatment by Peg-IFNα/RBV and by daclatasvir/asunaprevir treatment; they were 13.7→4.9 ng/mL on average for Peg-IFNα/RBV and 15.2→4.8 ng/mL for daclatasvir/asunaprevir. Moreover, the proportions of patients who showed below 5 ng/mL after SVR were 56% in Peg-IFNα/RBV and 65% in daclatasvir/asunaprevir treatment, suggesting nearly the same effect on AFP levels with both treatments. More recently, Miyaki et al[24] examined the changes in AFP levels before and after the dual therapy (median 27 mo after the completion of the therapy), and found a significant decrease in SVR patients (AFP levels decreased to within the normal limit in all patients by 18 mo after treatment).
Second is the potential of dual therapy with daclatasvir/asunaprevir to reduce liver fibrosis. Miyaki et al[24] also observed the changes of liver fibrosis markers before and after the administration of the drugs and found a significant increase in platelet counts and a significant decrease in liver fibrosis markers such as hyaluronic acid, type IV collagen and M2BPGi (a liver fibrosis glycobiomarker) at 27 mo (median) after completion of the treatment. van der Meer et al[27] also demonstrated a significant increase in the platelet counts associated with a decrease in spleen volume after the completion of IFN therapy.
There is some evidence that eradication of HCV-virus by IFN might bring about a decrease in the fibrosis staging score of HCV-associated chronic hepatitis. Shiratori et al[28] demonstrated that the fibrosis score after IFN therapy had regressed in patients with a sustained response at a rate of -0.28 U/year in the histological examination of the biopsied specimens, suggesting that the staging of fibrosis might be reduced by one step in every 4 years by IFN in SVR patients. And, it is well known that the staging of fibrosis has a close association with the incidence of HCC development[29]. Omata[29] surveyed the relationship between the degree of fibrosis and the incidence of HCC in HCV-associated chronic hepatitis and found that the incidence of HCC was 0.46%/year in patients with slight fibrosis (F1 stage), while in patients with moderate fibrosis (F3 stage) it was 3%/year, and in patients with severe fibrosis (F4 stage) it was 7%/year.
In support of this concept, van der Meer et al[27] demonstrated an increase in platelet counts associated with a decrease in spleen volume in the IFN-treated SVR patients among HCV-associated patients with Ishak 4-6 fibrosis, and concluded that the portal hypertension was decreased in those patients.
Considering the above evidence, it is possible that the eradication of HCV virus by dual therapy with daclatasvir/asunaprevir might bring about reduction in fibrosis and a lower incidence of HCC development even in patients over 75 years old, who have an impending risk of HCC development.
However, long-term observations of SVR patients after therapy with daclatasvir/asunaprevir will be necessary to make any final conclusions about the effect on prevention of HCC development.
Recently, direct acting antivirals (DAAs), including dual therapy with daclatasvir/asunaprevir, have been widely used in the therapy of chronic hepatitis C virus (HCV) genotype Ib infection. Dual therapy with daclatasvir/asunaprevir was demonstrated to be highly effective without serious side-effects. However, those results were studied in the non-elderly (patients under 70 years old). The effectiveness and safety in the elderly patients (> 70 years old) should be studied.
Although, DAAs were widely used in the treatment of HCV-associated liver diseases, few prior reports surveyed the difference in the efficacy and side effects of dual oral therapy with daclatasvir/asunaprevir between elderly patients and non-elderly patients.
In this study, the effectiveness and safety of the therapy with daclatasvir/asunaprevir were demonstrated in elderly patients as well as in non-elderly patients.
In Japanese, recently the aged population is increasing rapidly among cases of HCV-associated liver disease, and these individuals are at high risk for developing hepatocellular carcinoma. Eradicating HCV in this population is important and many approaches have been proposed. Now, the authors can eradicate HCV by oral therapy with daclatasvir/asunaprevir effectively and safely.
The manuscript is an interesting one, discussing a very important issue as regarding new DAAs with HCV treatment.
Manuscript source: Unsolicited manuscript
Specialty type: Gastroenterology and hepatology
Country of origin: Japan
Peer-review report classification
Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0
P- Reviewer: Conti B, El-Bendary MM S- Editor: Kong JX L- Editor: Filipodia E- Editor: Li D
| 1. | Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:742-748. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 284] [Cited by in F6Publishing: 303] [Article Influence: 25.3] [Reference Citation Analysis (0)] |
| 2. | Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655-662. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 191] [Cited by in F6Publishing: 210] [Article Influence: 19.1] [Reference Citation Analysis (0)] |
| 3. | Chayama K, Suzuki Y, Ikeda K, Toyota J, Karino Y, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N. All-oral combination of daclatasvir plus asunaprevir in interferon ineligible naive/intolerant and nonresponder Japanese patients chronically infected with HCV genotype 1b: Results from a phase 3 trial. The 64th Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC, November 1-5, 2013. Available from: http://www.hivandmore.de/kongresse/aasld2013/HCV_DAA_AASLD2013_AI447-026_Japan_DUAL_Ph3_Chayama_Oral_nr211.pdf. [Cited in This Article: ] |
| 4. | Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083-2091. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 468] [Cited by in F6Publishing: 488] [Article Influence: 48.8] [Reference Citation Analysis (0)] |
| 5. | Kurosaki M. Treatment strategy for eldery patients with chronic hepatitis C. Igakunoayumi. 2014;249:247-252. [Cited in This Article: ] |
| 6. | Kumada T, Toyoda H, Tada T. Treatment strategy for intractable HCV-associated chronic hepatitis-especially elderly patients. Medicina. 2015;52:319-321. [Cited in This Article: ] |
| 7. | Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010;52:518-527. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 221] [Cited by in F6Publishing: 224] [Article Influence: 16.0] [Reference Citation Analysis (0)] |
| 8. | Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649. [PubMed] [Cited in This Article: ] |
| 9. | Taura N, Hamasaki K, Nakao K, Ichikawa T, Nishimura D, Goto T, Fukuta M, Kawashimo H, Miyaaki H, Fujimoto M. Aging of patients with hepatitis C virus-associated hepatocellular carcinoma: long-term trends in Japan. Oncol Rep. 2006;16:837-843. [PubMed] [Cited in This Article: ] |
| 10. | Moriya T, Koyama T, Tanaka J, Mishiro S, Yoshizawa H. Epidemiology of hepatitis C virus in japan. Intervirology. 1999;42:153-158. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 1.4] [Reference Citation Analysis (0)] |
| 11. | Hiraoka A, Hidaka S, Shimizu Y, Utsunomiya H, Imai Y, Tatsukawa H, Tazuya N, Yamago H, Yorimitsu N, Tanihira T. Recent trends of Japanese hepatocellular carcinoma due to HCV in aging society. Hepatogastroenterology. 2012;59:1893-1895. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis (0)] |
| 12. | Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol. 2013;58:495-501. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 105] [Cited by in F6Publishing: 112] [Article Influence: 10.2] [Reference Citation Analysis (0)] |
| 13. | Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998;129:94-99. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 234] [Cited by in F6Publishing: 234] [Article Influence: 9.0] [Reference Citation Analysis (0)] |
| 14. | Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124-1130. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 367] [Cited by in F6Publishing: 356] [Article Influence: 14.2] [Reference Citation Analysis (0)] |
| 15. | Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131:174-181. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 833] [Cited by in F6Publishing: 760] [Article Influence: 30.4] [Reference Citation Analysis (0)] |
| 16. | Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, Ishibashi H, Yamada G, Yokosuka O, Shiratori Y. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut. 2004;53:425-430. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 125] [Cited by in F6Publishing: 130] [Article Influence: 6.5] [Reference Citation Analysis (0)] |
| 17. | Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579-587. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 490] [Cited by in F6Publishing: 470] [Article Influence: 27.6] [Reference Citation Analysis (0)] |
| 18. | Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol. 2007;79:1485-1490. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
| 19. | Sezaki H, Suzuki F, Kumada H. Effectiveness and long-term observation in dual therapy with daclatasvir and asunaprevir in the patients with HCV-associated liver diseases. Kanzo. 2014;55 suppl:A706. [Cited in This Article: ] |
| 20. | Karino Y, Koseki I, Hige S. Improvement in liver-function and prevention effect of HCC development by the dual therapy with daclatasvir and asunaprevir in HCV-associated liver diseases. Kanzo. 2014;55 supple:A535. [Cited in This Article: ] |
| 21. | Shigeno S, Haruna Y, Sasaki Y, Abe J, Imai T, Torisumi C, Wakahara Y, Inoue K, Hasekawa N, Inoue T. Changes in AFP and AFP L3 levels in the course of the treatment with asunaprevir and daclatasvir in patients with HCV-associated chronic hepatitis. Kanzo. 2015;56 supple:A1037. [Cited in This Article: ] |
| 22. | Yamagata Y, Imai K, Sawai Y, Kokita K, Itakura G, Fukuda K, Sasuoka S, Tani M, Okabe S, Iwamoto H. Early therapeutic effect of dual therapy with daclatasvir and asunaprevir. Kanzo. 2015;56 supple:A1039. [Cited in This Article: ] |
| 23. | Shimada N, Atsukawa M, Abe H, Yoshizawa U, Tanaka Y, Thubota A, Aizawa Y. Genomic change in HCV and efficacy of the oral therapy with daclatasvir and asunaprevir and changes in alfa-fetoprotein levels. Kanzo. 2015;56 supple:A718. [Cited in This Article: ] |
| 24. | Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Aikata H, Hayes CN. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res. 2016;46:758-764. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis (0)] |
| 25. | Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, Kobayashi K. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 1990;12:680-687. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 277] [Cited by in F6Publishing: 258] [Article Influence: 7.6] [Reference Citation Analysis (0)] |
| 26. | Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61-66. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 260] [Cited by in F6Publishing: 243] [Article Influence: 8.1] [Reference Citation Analysis (0)] |
| 27. | van der Meer AJ, Maan R, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol. 2016;31:1168-1176. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
| 28. | Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517-524. [PubMed] [Cited in This Article: ] |
| 29. | Omata M. Clinical treatment of hepatitis including the aspect of the development of hepatocellular carcinoma. Tokyo, Medical Center, 1995: 1-103. . [Cited in This Article: ] |